中国实用外科杂志 ›› 2011, Vol. 31 ›› Issue (10): 894-896.

• 专家论坛 • 上一篇    下一篇

再谈早期乳腺癌诊治需要重视的几个问题

刘荫华,徐    玲   

  1. 北京大学第一医院外科,北京100034
  • 出版日期:2011-10-01 发布日期:2011-09-30

  • Online:2011-10-01 Published:2011-09-30

摘要:

2011年6月,国家卫生部发布了《乳腺癌诊疗规范》(2011年版),为进一步规范我国乳腺癌诊疗行为,保障医疗质量和医疗安全提供了依据。诊断优先、诊断方法规范应成为个体化治疗的基础。2011年3月St. Gallen 乳腺癌国际会议达成共识,推荐选择雌激素受体(ER)、孕激素受体(PR)、人表皮生长因子受体2(HER-2)及Ki67四项肿瘤分子标记物检查对乳腺癌分子分型进行区分,这一理念推动了乳腺癌从基于解剖学的分期诊断和基于常规组织病理检查的分级诊断向分子水平诊断的进步,并将为临床个体化治疗提供了新的参考。

关键词: 早期乳腺癌, 肿瘤分子标记物, 免疫组化

Abstract:

Further discussion on several concerns with diagnosis and treatment of early breast cancer        LIU Yin-hua, XU Ling. Department of Surgery, Peking University First Hospital,Beijing100034,China
Corresponding author: LIU Yin-hua,E-mail: liuyinhua@medmail.com.cn
Abstract    In June 2011 the Ministry of Health of the People’s Republic of China published “the Standard Diagnosis and Treatment of Breast Cancer”. It is not only beneficial to improve the quality of the breast cancer treatment, but also provide the criteria of medical behavior. Individualized treatment is based on accurate diagnosis in priority and followed by standard therapy. In March 2011 the International St. Gallen Consensus on the Treatment of Early Breast Cancer recommended that the immunohistochemical definition of ER, PR, the detection of overexpression and/or amplification of the HER-2 oncogene, and Ki67 labeling index were used to identify tumor subtypes. The definition of biological subtypes means that the knowledge about breast cancer developed from the TNM stage based on anatomy and histology grade based on histopathology to subtypes based on molecular level. And systemic treatment recommendations for subtypes were useful for the evidence based individualized treatment.

Key words: early breast cancer, tumor molecular markers, immunohistochemistry